Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
This Weight Loss Stock Could Soar Over 220%, According to Wall Street. Time to Buy?
Wall Street is bullish on Viking, but the company still has a lot to prove. Viking has a number of different clinical studies ...
pharmaphorum23h
High-dose semaglutide ramps up weight loss, says Novo
with a 20.4% reduction in weight in the REDEFINE 1 study over 68 weeks that fell short of Novo Nordisk's hope of a 25% loss. At the least, the new 7.2mg results point to scope for hiking the ...
pharmaphorum23h
Novo Nordisk buys another obesity biotech
potentially pointing to potential for use in tandem with other weight-loss therapies, including Novo Nordisk's GLP-1 drug Wegovy (semaglutide). Brian Finan, head of obesity research at Novo ...
wusf9h
About half of Americans approve of using weight-loss drugs to treat obesity, a poll finds
The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar ...
7NEWS23h
Weight Loss
The singer reflected on being ‘so broken and dark’ a year ago.